Creative Medical Technology Holdings Provides Corporate Update
Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (
NASDAQCELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Creative Medical Technology Holdings, Inc., (
NASDAQCELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals.
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
Creative Medical Technology Holdings, Inc. (
NASDAQCELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelzTM. This cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals dealing with brittle Type 1 diabetes, a condition characterized by extreme fluctuations in blood glucose levels.
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (
NASDAQCELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it has engaged Syneos Health
NASDAQ: SYNHNASDAQSYNH)
Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (
NASDAQCELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced positive three-year follow-up data for the Company's StemSpine® pilot study. The three-year data demonstrates continued efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.
